gip/glp-1 receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Dual GIP/GLP-1 receptor agonists: New

Drug Interactions: Combining GLP-1 medications with SGLT2 inhibitors may enhance heart and kidney health, but caution is needed with insulin or sulfonylureas

Large-scale, multi-center studies and clinical trials will be essential to confirm these findings and refine guidelines for patients at risk

Binding of GLP-1 or a synthetic hormone receptor agonist to the GLP-1R on the surface of HEK-Blue GLP-1 cells triggers a signaling cascade leading to the activation of the CRE-binding Protein (CREB) pathway and the subsequent production of SEAP

doi: 10.1016/j.jss.2025.05.016

New triple-acting hybrid peptides show potential as obesity therapies in knock-out mice [297]

Tested according to USP 85 to confirm absence of harmful bacterial endotoxins